BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017;152:1090-1099.e1. [PMID: 28088461 DOI: 10.1053/j.gastro.2017.01.003] [Cited by in Crossref: 387] [Cited by in F6Publishing: 399] [Article Influence: 64.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Lu J, Xu Q, Chen B, Shen L. The association between serum folate and ultrasound - defined hepatic steatosis. Ann Med 2023;55:456-62. [PMID: 36647694 DOI: 10.1080/07853890.2023.2168042] [Reference Citation Analysis]
2 Dodge JL, Lee BT, Kassem ACZ, Biggins SW, Rana PA, Nadim MK, Asrani SK, Fong TL. The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation. Transplantation 2023;107:429-37. [PMID: 36194998 DOI: 10.1097/TP.0000000000004311] [Reference Citation Analysis]
3 Peleman C, De Vos WH, Pintelon I, Driessen A, Van Eyck A, Van Steenkiste C, Vonghia L, De Man J, De Winter BY, Vanden Berghe T, Francque SM, Kwanten WJ. Zonated quantification of immunohistochemistry in normal and steatotic livers. Virchows Arch 2023. [PMID: 36702937 DOI: 10.1007/s00428-023-03496-8] [Reference Citation Analysis]
4 Kaplan JM, Alexis J, Grimaldi G, Islam M, Izard SM, Lee TP. A comparison of magnetic resonance elastography (MRE) to biomarker testing for staging fibrosis in non-alcoholic fatty liver disease (NAFLD). Transl Gastroenterol Hepatol 2023;8:7. [PMID: 36704653 DOI: 10.21037/tgh-22-27] [Reference Citation Analysis]
5 Zhi G, Shao B, Zheng T, Mu J, Li J, Feng Y, Zhu S, Dang Y, Liu F, Wang D. Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1082451] [Reference Citation Analysis]
6 Lutsiv T, Mcginley JN, Neil ES, Foster MT, Thompson HJ. Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis. Nutrients 2023;15:526. [DOI: 10.3390/nu15030526] [Reference Citation Analysis]
7 Barrientos-Riosalido A, Real M, Bertran L, Aguilar C, Martínez S, Parada D, Vives M, Sabench F, Riesco D, Castillo DD, Richart C, Auguet T. Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. Int J Mol Sci 2023;24. [PMID: 36674839 DOI: 10.3390/ijms24021324] [Reference Citation Analysis]
8 Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] [Reference Citation Analysis]
9 Dong TS, Katzka W, Yang JC, Chang C, Arias-Jayo N, Lagishetty V, Balioukova A, Chen Y, Dutson E, Li Z, Mayer EA, Pisegna JR, Sanmiguel C, Jacobs JP. Microbial changes from bariatric surgery alters glucose-dependent insulinotropic polypeptide and prevents fatty liver disease. Gut Microbes 2023;15:2167170. [PMID: 36732495 DOI: 10.1080/19490976.2023.2167170] [Reference Citation Analysis]
10 Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol 2023;21:143-152.e3. [PMID: 34999207 DOI: 10.1016/j.cgh.2021.12.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
12 Meunier L, Belkacemi M, Pageaux GP, Radenne S, Vallet-Pichard A, Houssel-Debry P, Duvoux C, Botta-Fridlund D, de Ledinghen V, Conti F, Anty R, Di Martino V, Debette-Gratien M, Leroy V, Gerster T, Lebray P, Alric L, Abergel A, Dumortier J, Besch C, Montialoux H, Samuel D, Duclos-Vallée JC, Coilly A. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years? Viruses 2022;15. [PMID: 36680177 DOI: 10.3390/v15010137] [Reference Citation Analysis]
13 Chen S, Tang L, Guillot A, Liu H. Bariatric Surgery Associates with Nonalcoholic Steatohepatitis/Hepatocellular Carcinoma Amelioration via SPP1 Suppression. Metabolites 2022;13. [PMID: 36676937 DOI: 10.3390/metabo13010011] [Reference Citation Analysis]
14 Fernández-Carrillo C, Li Y, Ventura-Cots M, Argemi J, Dai D, Clemente-Sánchez A, Duarte-Rojo A, Behari J, Ganesh S, Jonassaint NL, Tevar AD, Hughes CB, Humar A, Molinari M, Landsittel DP, Bataller R. Poor Outcomes of Patients With NAFLD and Moderate Renal Dysfunction or Short-Term Dialysis Receiving a Liver Transplant Alone. Transpl Int 2022;35:10443. [PMID: 36568138 DOI: 10.3389/ti.2022.10443] [Reference Citation Analysis]
15 Ding T, Chen S, Xiao W, Liu Z, Tu J, Yu Y, Dong B, Chen W, Zeng Y. Six-Transmembrane Epithelial Antigen of Prostate 3 Promotes Hepatic Insulin Resistance and Steatosis. J Lipid Res 2023;64:100318. [PMID: 36495944 DOI: 10.1016/j.jlr.2022.100318] [Reference Citation Analysis]
16 Ramaswamy K, Madariaga HM, Zheng L, Thomas B, Lerma EV. Donor derived infections in kidney transplant. Dis Mon 2022;68:101330. [PMID: 35221018 DOI: 10.1016/j.disamonth.2022.101330] [Reference Citation Analysis]
17 Dangl M, Grant JK, Vincent L, Ebner B, Maning J, Olorunfemi O, Zablah G, Sancassani R, Colombo R. The association of pre-transplant atrial fibrillation with in-hospital outcomes in patients undergoing orthotopic liver transplantation: A propensity score matching analysis. J Card Surg 2022;37:4762-73. [PMID: 36403274 DOI: 10.1111/jocs.17183] [Reference Citation Analysis]
18 Khalayleh H, Imam A, Ovadya R, Aizner S, Braun M, Safadi R, Nesher E, Khalaileh A. Effect of Age on Liver Transplantation Recipient Outcomes: Two Centers’ Experience. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.10.055] [Reference Citation Analysis]
19 Manzia TM, Trapani S, Nardi A, Ricci A, Lenci I, Milana M, Angelico R, De Feo TM, Agnes S, Andorno E, Baccarani U, Carraro A, Cescon M, Cillo U, Colledan M, De Carlis L, De Simone P, Di Benedetto F, Ettorre GM, Gruttadauria S, Lupo LG, Mazzaferro V, Romagnoli R, Rossi G, Rossi M, Spada M, Vennarecci G, Vivarelli M, Zamboni F, Tisone G, Cardillo M, Angelico M. Temporal trends of waitlistings for liver transplantation in Italy: The ECALITA (Evolution of IndiCAtion in LIver transplantation in ITAly) registry study. Dig Liver Dis 2022;54:1664-71. [PMID: 36096992 DOI: 10.1016/j.dld.2022.08.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yakıştıran B, Tanaçan A, Altınboğa O, Elbayiyev S, Canpolat FE, Yücel A. Fetal pulmonary artery Doppler parameters in pregnancies complicated with intrahepatic cholestasis of pregnancy: a prospective case-control study. J Turkish German Gynecol Assoc 2022;23:249-254. [DOI: 10.4274/jtgga.galenos.2021.2021-9-21] [Reference Citation Analysis]
21 Sato S, Kawai H, Sato S, Iwasaki H, Omori M, Kita Y, Ikeda Y, Awatsu T, Murata A, Taniguchi G, Shimada Y, Genda T. Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. BMC Gastroenterol 2022;22:478. [PMID: 36411436 DOI: 10.1186/s12876-022-02575-5] [Reference Citation Analysis]
22 Wang J, Liu J, Liu Y, Xue R, Zhan J, Jiang S, Wang L, Yan X, Xiong Y, Xia J, Yin S, Tong X, Chen Y, Li J, Huang R, Wu C. Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease. Hepatol Res 2022. [PMID: 36317959 DOI: 10.1111/hepr.13854] [Reference Citation Analysis]
23 Klang E, Soffer S, Alper L, Shimon O, Barash Y, Davidov Y, Likhter M, Cohen‐ezra O, Ben Yakov G, Ben‐ari Z. Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.805] [Reference Citation Analysis]
24 Hong SB, Lee NK, Kim S, Um K, Kim K, Kim IJ. Hepatic Fat Quantification with the Multi-Material Decomposition Algorithm by Using Low-Dose Non-Contrast Material-Enhanced Dual-Energy Computed Tomography in a Prospectively Enrolled Cohort. Medicina (Kaunas) 2022;58. [PMID: 36295617 DOI: 10.3390/medicina58101459] [Reference Citation Analysis]
25 Wakil A, Mohamed M, Tafesh Z, Niazi M, Olivo R, Xia W, Greenberg P, Pyrsopoulos N. Trends in hospitalization for alcoholic hepatitis from 2011 to 2017: A USA nationwide study. World J Gastroenterol 2022; 28(34): 5036-5046 [DOI: 10.3748/wjg.v28.i34.5036] [Reference Citation Analysis]
26 Fetzer DT, Rosado-Mendez IM, Wang M, Robbin ML, Ozturk A, Wear KA, Ormachea J, Stiles TA, Fowlkes JB, Hall TJ, Samir AE. Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. Radiology 2022;:212808. [PMID: 36098640 DOI: 10.1148/radiol.212808] [Reference Citation Analysis]
27 Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022;56:942-56. [PMID: 35880713 DOI: 10.1111/apt.17158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
28 Zeng C, Chen M. Progress in Nonalcoholic Fatty Liver Disease: SIRT Family Regulates Mitochondrial Biogenesis. Biomolecules 2022;12:1079. [PMID: 36008973 DOI: 10.3390/biom12081079] [Reference Citation Analysis]
29 Jiang W, Mao X, Liu Z, Zhang T, Jin L, Chen X. Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019: Findings From the Global Burden of Disease Study 2019. J Clin Gastroenterol 2022. [PMID: 35921320 DOI: 10.1097/MCG.0000000000001739] [Reference Citation Analysis]
30 Mehrabi A, Ramouz A, Golriz M, Khajeh E, Hackert T, Müller-Stich B, Strobel O, Hoffmann K, Büchler MW; Liver Cancer Center Heidelberg (LCCH). Long-Term Outcomes of Mesohepatectomy for Centrally Located Liver Tumors: Two-Decade Single-Center Experience. J Am Coll Surg 2022;235:257-66. [PMID: 35839400 DOI: 10.1097/XCS.0000000000000209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Castera L, Boursier J. Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. Semin Liver Dis 2022;42:313-26. [PMID: 35835440 DOI: 10.1055/s-0042-1751081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Marie S, Frost KL, Hau RK, Martinez-guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Howell J, Majumdar A, Fink M, Byrne M, Mccaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Gane E, Thompson A, Gow P. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. Transplantation Direct 2022;8:e1345. [DOI: 10.1097/txd.0000000000001345] [Reference Citation Analysis]
34 Gao M, Xin J, Li X, Gao L, Shao S, Zhao M, Zhao E. Differential Expression Profiles of mRNA and Noncoding RNA and Analysis of Competitive Endogenous RNA Regulatory Networks in Nonalcoholic Steatohepatitis. Gastroenterology Research and Practice 2022;2022:1-13. [DOI: 10.1155/2022/3200932] [Reference Citation Analysis]
35 Rattan P, Shah VH. Review article: current and emerging therapies for acute alcohol-associated hepatitis. Aliment Pharmacol Ther 2022;56:28-40. [PMID: 35567372 DOI: 10.1111/apt.16969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. Yonsei Med J 2022;63:619-31. [PMID: 35748073 DOI: 10.3349/ymj.2022.63.7.619] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Balkhed W, Åberg FO, Nasr P, Ekstedt M, Kechagias S. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study. Liver Int 2022;42:1545-56. [PMID: 35319156 DOI: 10.1111/liv.15255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ramanathan R, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. IJMS 2022;23:7280. [DOI: 10.3390/ijms23137280] [Reference Citation Analysis]
39 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
41 Philip G, Hookey L, Richardson H, Flemming JA. Alcohol-associated Liver Disease Is Now the Most Common Indication for Liver Transplant Waitlisting Among Young American Adults. Transplantation 2022. [PMID: 35642977 DOI: 10.1097/TP.0000000000004202] [Reference Citation Analysis]
42 Liao C, Huang P, Chien H, Lin T, Yeh C, Lin K. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1232. [DOI: 10.3390/biomedicines10061232] [Reference Citation Analysis]
43 Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, Xie X. Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults. JAMA Dermatol 2022. [PMID: 35612851 DOI: 10.1001/jamadermatol.2022.1609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Delacôte C, Favre M, El Amrani M, Ningarhari M, Lemaitre E, Ntandja-Wandji LC, Bauvin P, Boleslawski E, Millet G, Truant S, Mathurin P, Louvet A, Canva V, Lebuffe G, Pruvot FR, Dharancy S, Lassailly G; French ABM study group. Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study. United European Gastroenterol J 2022. [PMID: 35470965 DOI: 10.1002/ueg2.12226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Shen NT, Kaplan AJ, Fox AN, Brown RS. Liver transplantation. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch100] [Reference Citation Analysis]
46 Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2022;54:500-8. [PMID: 34799282 DOI: 10.1016/j.dld.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology 2022;75:968-82. [PMID: 34662439 DOI: 10.1002/hep.32203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Saitta C, Caruso A, Maimone S, Filomia R, Cacciola I, Caccamo G, Franzè MS, Pitrone C, Alibrandi A, Gaeta M, Mandraffino G, Squadrito G, Raimondo G. Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. Intern Emerg Med 2022. [PMID: 35332431 DOI: 10.1007/s11739-022-02971-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Habash NW, Sehrawat TS, Shah VH, Cao S. Epigenetics of alcohol-related liver diseases. JHEP Rep 2022;4:100466. [PMID: 35462859 DOI: 10.1016/j.jhepr.2022.100466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
51 Tayob N, Lok ASF, Feng Z. A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Stat Med 2022. [PMID: 35199349 DOI: 10.1002/sim.9358] [Reference Citation Analysis]
52 Zhou Z, Ren Q, Jiao S, Cai Z, Geng X, Deng L, Wang B, Hu L, Zhang L, Yang Y, Li Z. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. Eur J Med Chem 2022;229:114061. [PMID: 34954593 DOI: 10.1016/j.ejmech.2021.114061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Howell J, Majumdar A, Fink MA, Byrne M, McCaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Munn S, Gane E, Thompson AJ, Gow P. Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. Liver Transpl 2022;28:236-46. [PMID: 34624175 DOI: 10.1002/lt.26329] [Reference Citation Analysis]
54 Kumar SR, Khatana SAM, Goldberg D. Impact of Medicaid Expansion on Liver-Related Mortality. Clin Gastroenterol Hepatol 2022;20:419-426.e1. [PMID: 33278572 DOI: 10.1016/j.cgh.2020.11.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
55 Moreno-vedia J, Girona J, Ibarretxe D, Masana L, Rodríguez-calvo R. Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. Biomedicines 2022;10:197. [DOI: 10.3390/biomedicines10010197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Farooq M, Hameed H, Dimanche-Boitrel MT, Piquet-Pellorce C, Samson M, Le Seyec J. Switching to Regular Diet Partially Resolves Liver Fibrosis Induced by High-Fat, High-Cholesterol Diet in Mice. Nutrients 2022;14:386. [PMID: 35057565 DOI: 10.3390/nu14020386] [Reference Citation Analysis]
57 Goyes D, Danford CJ, Nsubuga JP, Bonder A. Waitlist mortality and transplant free survival in Hispanic patients listed for liver transplant using the UNOS database. Ann Hepatol 2021;23:100304. [PMID: 33444852 DOI: 10.1016/j.aohep.2021.100304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 董 方. The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease. ACM 2022;12:11399-11404. [DOI: 10.12677/acm.2022.12121643] [Reference Citation Analysis]
59 Gambato M, Ferrarese A. Indications to Liver Transplantation for Liver Cirrhosis. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_2] [Reference Citation Analysis]
60 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. Jpn J Med Ultrasonics 2022;49:385-396. [DOI: 10.3179/jjmu.jjmu.r.201] [Reference Citation Analysis]
61 Didenko VI, Klenina IA, Tatarchuk ОM, Hrabovska OI, Petishko OP. Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases. Regul Mech Biosyst 2022;13:3-9. [DOI: 10.15421/022201] [Reference Citation Analysis]
62 Decharatanachart P, Chaiteerakij R, Tiyarattanachai T, Treeprasertsuk S. Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211062807. [PMID: 34987607 DOI: 10.1177/17562848211062807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Goyes D, Nsubuga JP, Medina-Morales E, Barba R, Patwardhan V, Saberi B, Fricker Z, Bonder A. Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points. J Clin Med 2021;10:5826. [PMID: 34945122 DOI: 10.3390/jcm10245826] [Reference Citation Analysis]
64 Venkateswaran N, Weismiller S, Krok K. Recurrent NASH Post-liver Transplant: Implications and Treatment. Curr Hepatology Rep 2021;20:108-116. [DOI: 10.1007/s11901-021-00569-7] [Reference Citation Analysis]
65 Kaplan A, Brown RS. HCV and Liver Transplantation. Curr Hepatology Rep 2021;20:191-197. [DOI: 10.1007/s11901-021-00580-y] [Reference Citation Analysis]
66 Córdova-Gallardo J, Keaveny AP, Qi X, Méndez-Sánchez N. Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems. Eur J Gastroenterol Hepatol 2021;33:e84-93. [PMID: 34985050 DOI: 10.1097/MEG.0000000000002335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Wahid NA, Lee J, Kaplan A, Fortune BE, Safford MM, Brown RS Jr, Rosenblatt R. Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage. Liver Transpl 2021;27:1723-32. [PMID: 34118120 DOI: 10.1002/lt.26209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
68 Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. Hepatology 2021;74:3330-44. [PMID: 34174003 DOI: 10.1002/hep.32032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
69 Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84. [PMID: 34453963 DOI: 10.1016/j.jhep.2021.08.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 22.0] [Reference Citation Analysis]
70 Bailey DE Jr, Zucker DM. Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature. Gastroenterol Nurs 2020;43:E172-83. [PMID: 33003028 DOI: 10.1097/SGA.0000000000000488] [Reference Citation Analysis]
71 Valenti L, Pelusi S, Aghemo A, Gritti S, Pasulo L, Bianco C, Iegri C, Cologni G, Degasperi E, D'Ambrosio R, Del Poggio P, Soria A, Puoti M, Carderi I, Pigozzi MG, Carriero C, Spinetti A, Zuccaro V, Memoli M, Giorgini A, Viganò M, Rumi MG, Re T, Spinelli O, Colombo MC, Quirino T, Menzaghi B, Lorini G, Pan A, D'Arminio Monforte A, Buscarini E, Autolitano A, Bonfanti P, Terreni N, Aimo G, Mendeni M, Prati D, Lampertico P, Colombo M, Fagiuoli S; NAVIGATORE-Lombardia Network. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. Hepatol Commun 2021. [PMID: 34811949 DOI: 10.1002/hep4.1851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am 2022;102:117-37. [PMID: 34800381 DOI: 10.1016/j.suc.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021;41:461-75. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
74 Kotlyarov S, Bulgakov A. Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease. Cells 2021;10:2978. [PMID: 34831201 DOI: 10.3390/cells10112978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
75 Sohrabi M, Gholami A, Taheri M, Fekri S, Amirkalali B, Hatami S, Hajbaba M, Fallah Tolbar H, Aghili S, Zamani F, NasiriToosi M, Keyvani H. Melatonin Levels in Patients with Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals according to Fibrosis Level. Middle East J Dig Dis 2021;13:109-14. [PMID: 34712448 DOI: 10.34172/mejdd.2021.213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Kawakatsu-Hatada Y, Murata S, Mori A, Kimura K, Taniguchi H. Serous Membrane Detachment with Ultrasonic Homogenizer Improves Engraftment of Fetal Liver to Liver Surface in a Rat Model of Cirrhosis. Int J Mol Sci 2021;22:11589. [PMID: 34769019 DOI: 10.3390/ijms222111589] [Reference Citation Analysis]
77 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Yan Y, Ren L, Liu Y, Liu L. Long non-coding RNA CRNDE as potential biomarkers facilitate inflammation and apoptosis in alcoholic liver disease. Aging (Albany NY) 2021;13:23233-44. [PMID: 34633988 DOI: 10.18632/aging.203614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Masson S, Aldersley H, Leithead JA, Day E, Langford A, Healy P, O'Grady J, Thorburn D, Parker C, Shepherd L, Arndtz K, Webb K, Holt A. Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral. Lancet Gastroenterol Hepatol 2021;6:947-55. [PMID: 34626562 DOI: 10.1016/S2468-1253(21)00195-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 Wen W, Wu P, Zhang Y, Chen Z, Sun J, Chen H. Comprehensive Analysis of NAFLD and the Therapeutic Target Identified. Front Cell Dev Biol 2021;9:704704. [PMID: 34616724 DOI: 10.3389/fcell.2021.704704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Ma C, Qian AS, Nguyen NH, Stukalin I, Congly SE, Shaheen AA, Swain MG, Teriaky A, Asrani SK, Singh S. Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. Am J Gastroenterol 2021;116:2060-7. [PMID: 33998785 DOI: 10.14309/ajg.0000000000001292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 McCarron S, Bathon B, Conlon DM, Abbey D, Rader DJ, Gawronski K, Brown CD, Olthoff KM, Shaked A, Raabe TD. Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH. Hepatology 2021;74:1825-44. [PMID: 33901295 DOI: 10.1002/hep.31857] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
83 Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res 2021;49:3000605211047074. [PMID: 34590877 DOI: 10.1177/03000605211047074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
84 Ren S, Ma X, Wang R, Liu H, Wei Y, Wei S, Jing M, Zhao Y. Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. Front Pharmacol 2021;12:742465. [PMID: 34566663 DOI: 10.3389/fphar.2021.742465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, Trotti R, Malvestiti F, D'Ambrosio R, Lampertico P, Colli A, Colombo M, Tsochatzis EA, Fraquelli M, Prati D. Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatol Commun 2021;5:1824-32. [PMID: 34520121 DOI: 10.1002/hep4.1794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
86 Watt KD, Heimbach JK, Rizk M, Jaruvongvanich P, Sanchez W, Port J, Venkatesh SK, Bamlet H, Tiedtke K, Malhi H, Acosta Cardenas A, Grothe K, Clark M, Mundi MS, Abu Dayyeh BK. Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation. Liver Transpl 2021;27:1239-47. [PMID: 33866660 DOI: 10.1002/lt.26074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Schlegel A, Foley DP, Savier E, Flores Carvalho M, De Carlis L, Heaton N, Taner CB. Recommendations for Donor and Recipient Selection and Risk Prediction: Working Group Report From the ILTS Consensus Conference in DCD Liver Transplantation. Transplantation 2021;105:1892-903. [PMID: 34416750 DOI: 10.1097/TP.0000000000003825] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
88 Fang X, Wang H, Ye T, Fu X, Tan X, Zeng Y, Fan J, Xu Y. Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis 2021;20:96. [PMID: 34461919 DOI: 10.1186/s12944-021-01518-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3627-45. [PMID: 34408459 DOI: 10.2147/DMSO.S304357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Lee MCM, Kachura JJ, Vlachou PA, Dzulynsky R, Di Tomaso A, Samawi H, Baxter N, Brezden-Masley C. Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Curr Oncol 2021;28:3030-40. [PMID: 34436031 DOI: 10.3390/curroncol28040265] [Reference Citation Analysis]
91 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 VanDerwerken DN, Wood NL, Segev DL, Gentry SE. The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant. Hepatology 2021;74:950-60. [PMID: 33655565 DOI: 10.1002/hep.31781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Wong RJ, Hirode G. The Effect of Hospital Safety-Net Burden and Patient Ethnicity on In-Hospital Mortality Among Hospitalized Patients With Cirrhosis. J Clin Gastroenterol 2021;55:624-30. [PMID: 33136780 DOI: 10.1097/MCG.0000000000001452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Driedger M, Vachon M, Wong A, Conway B, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld J, Lee SS, Cooper C. Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. CanLivJ 2021;4:283-91. [DOI: 10.3138/canlivj-2021-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Sharma A, Rawal P, Tripathi DM, Alodiya D, Sarin SK, Kaur S, Ghosh S. Upgrading Hepatic Differentiation and Functions on 3D Printed Silk-Decellularized Liver Hybrid Scaffolds. ACS Biomater Sci Eng 2021;7:3861-73. [PMID: 34318665 DOI: 10.1021/acsbiomaterials.1c00671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
96 Kaur N, Emamaullee J, Lian T, Lo M, Ender P, Kahn J, Sher L. Impact of Morbid Obesity on Liver Transplant Candidacy and Outcomes: National and Regional Trends. Transplantation 2021;105:1052-60. [PMID: 33741845 DOI: 10.1097/TP.0000000000003404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
97 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Sheraliev AR, Polikarpov AA, Tileubergenov II, Moiseenko AV, Granov DA. A case report on intraportal injection of autologous bone marrow-derived mononuclear cells and liver transplantation in a patient with cirrhosis. RJTAO 2021;23:88-94. [DOI: 10.15825/1995-1191-2021-2-88-94] [Reference Citation Analysis]
99 Dong TS, Luu K, Lagishetty V, Sedighian F, Woo SL, Dreskin BW, Katzka W, Chang C, Zhou Y, Arias-Jayo N, Yang J, Ahdoot AI, Ye J, Li Z, Pisegna JR, Jacobs JP. The Intestinal Microbiome Predicts Weight Loss on a Calorie-Restricted Diet and Is Associated With Improved Hepatic Steatosis. Front Nutr 2021;8:718661. [PMID: 34307440 DOI: 10.3389/fnut.2021.718661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
100 Ivanics T, Shwaartz C, Claasen MPAW, Patel MS, Yoon P, Raschzok N, Wallace D, Muaddi H, Murillo Perez CF, Hansen BE, Selzner N, Sapisochin G. Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transpl Int 2021;34:1444-54. [PMID: 33977568 DOI: 10.1111/tri.13903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Vorobioff JD, Contreras F, Tanno F, Hernández L, Bessone F, Colombato L, Adi J, Fassio E, Felgueres M, Fernández G, Gaite L, Gibelli D, Darrichon HG, Lafage M, Lombardo D, López S, Mateo A, Mendizábal M, Pecoraro J, Ruf A, Ruiz P, Severini J, Stieben T, Sixto M, Zárate F, Barraza SB, Sierra ID, Pacheco VR, Roblero JP, Rojas JO, González PR, Rodríguez DSM, Sierralta A, Manchego AU, Valdes E, Yaquich P, Wolff R, Valdivia FB, Gallegos RC, Galloso R, Marcelo JS, Montes P, Tenorio L, Veramendi I, Alava E, Armijos X, Benalcazar G, Carrera E, Pazmiño GF, Díaz EM, Garassini M, Marrero RP, Infante M, Suárez DP, Gutiérrez JC, Reyes CMV, Serrano YM, Hernández RH, Martínez OM, González TP, Andara MT, Hernández MS, Gerona S, García I, Tijera F, López EP, Torres K, Garzón M. A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Ann Hepatol 2020;19:396-403. [PMID: 32418749 DOI: 10.1016/j.aohep.2020.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol 2021;9:428-35. [PMID: 34221929 DOI: 10.14218/JCTH.2020.00072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Dong TS, Luu K, Lagishetty V, Sedighian F, Woo SL, Dreskin BW, Katzka W, Chang C, Zhou Y, Arias-Jayo N, Yang J, Ahdoot AI, Ye J, Li Z, Pisegna JR, Jacobs JP. Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease. Hepatoma Res 2021;7. [PMID: 36713356 DOI: 10.20517/2394-5079.2021.55] [Reference Citation Analysis]
104 Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:404-14. [PMID: 33948067 DOI: 10.20524/aog.2021.0604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
105 Saydmohammed M, Jha A, Mahajan V, Gavlock D, Shun TY, DeBiasio R, Lefever D, Li X, Reese C, Kershaw EE, Yechoor V, Behari J, Soto-Gutierrez A, Vernetti L, Stern A, Gough A, Miedel MT, Lansing Taylor D. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. Exp Biol Med (Maywood) 2021;:15353702211009228. [PMID: 33957803 DOI: 10.1177/15353702211009228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Locke JE, Shelton B, Orandi B, Olthoff K, Pomfret E, Forde KA, Sawinski D, Gray M, Ascher N. Obesity is a risk factor for progression to kidney transplant waitlisting after liver transplantation. Clin Transplant 2021;35:e14317. [PMID: 33866616 DOI: 10.1111/ctr.14317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Molinari M, Fernandez-Carrillo C, Dai D, Dana J, Clemente-Sanchez A, Dharmayan S, Kaltenmeier C, Liu H, Behari J, Rachakonda V, Ganesh S, Hughes C, Tevar A, Al Harakeh H, Emmanuel B, Humar A, Bataller R. Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis. Transpl Int 2021;34:1105-22. [PMID: 33780554 DOI: 10.1111/tri.13873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Wu YC, Chuang PM, Pinotti R, Nagirimadugu A, Valentin N, Dinani A. The association of impaired lung function and nonalcoholic fatty liver disease: a systematic review. Eur J Gastroenterol Hepatol 2021;33:745-51. [PMID: 33394807 DOI: 10.1097/MEG.0000000000001967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Semin Liver Dis 2021;41:213-24. [PMID: 33992030 DOI: 10.1055/s-0041-1725023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
110 Weinberg EM, Trinh HN, Firpi RJ, Bhamidimarri KR, Klein S, Durlam J, Watkins S, Reddy KR, Weiss M, Zink RC, Lok AS. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clin Gastroenterol Hepatol 2021;19:996-1008.e6. [PMID: 32629123 DOI: 10.1016/j.cgh.2020.06.066] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
111 Sundaram V, Jalan R, Shah P, Singal AK, Patel AA, Wu T, Noureddin M, Mahmud N, Wong RJ. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. Hepatology 2021;73:1932-44. [PMID: 32961608 DOI: 10.1002/hep.31566] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
112 Zhou J, Huang Z, Chen Z, Xu F, Tong R, Zheng S. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database. BMC Gastroenterol 2021;21:195. [PMID: 33931011 DOI: 10.1186/s12876-021-01786-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, Dahlqvist Leinhard O, Ebbers T, Alfredsson J, Carlhäll CJ, Lundberg P, Kechagias S, Ekstedt M. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol 2021;21:180. [PMID: 33879084 DOI: 10.1186/s12876-021-01763-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
114 Li C, Zhou W, Li M, Shu X, Zhang L, Ji G. Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway. Biomed Pharmacother 2021;139:111587. [PMID: 33865013 DOI: 10.1016/j.biopha.2021.111587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
115 Weinberg EM, Curry MP, Frenette CT, Regenstein FG, Schiff ER, Goodman ZD, Robinson JM, Chan JL, Imperial JC, Reddy KR. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. Liver Transpl 2021;27:568-79. [PMID: 33164276 DOI: 10.1002/lt.25934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
116 Gough A, Soto-Gutierrez A, Vernetti L, Ebrahimkhani MR, Stern AM, Taylor DL. Human biomimetic liver microphysiology systems in drug development and precision medicine. Nat Rev Gastroenterol Hepatol 2021;18:252-68. [PMID: 33335282 DOI: 10.1038/s41575-020-00386-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
117 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl 2021;27:548-57. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
118 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
119 Kohli R, Bove KE, Xanthakos SA. Non-Alcoholic Fatty Liver Disease in Children. Liver Disease in Children 2021. [DOI: 10.1017/9781108918978.036] [Reference Citation Analysis]
120 Kalyesubula M, Mopuri R, Asiku J, Rosov A, Yosefi S, Edery N, Bocobza S, Moallem U, Dvir H. High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. Dis Model Mech 2021;14:dmm048355. [PMID: 33608323 DOI: 10.1242/dmm.048355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
121 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
122 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Patton H, Heimbach J, McCullough A. AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol 2021;19:436-45. [PMID: 33393473 DOI: 10.1016/j.cgh.2020.10.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
124 Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol 2021;74:716-33. [PMID: 33212088 DOI: 10.1016/j.jhep.2020.11.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
125 Bojunga J, Geier A. Diabetes mellitus und Fettlebererkrankungen. Gastroenterologe 2021;16:109-119. [DOI: 10.1007/s11377-021-00510-w] [Reference Citation Analysis]
126 Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP Rep 2021;3:100261. [PMID: 34036255 DOI: 10.1016/j.jhepr.2021.100261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
127 Gardona R, Appel F, Ercolin S, Carvalho-Filho RJ, Barbosa DA, Ferraz ML. Evaluation of a strategy for identification of hepatitis C virus carriers in outpatient and emergency units: contribution to the microelimination of hepatitis C in Brazil. Braz J Infect Dis 2021;25:101546. [PMID: 33636108 DOI: 10.1016/j.bjid.2021.101546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Lembach Jahnsen H, Mergental H, Perera MTPR, Mirza DF. Ex-situ liver preservation with machine preservation. Curr Opin Organ Transplant 2021;26:121-32. [PMID: 33650995 DOI: 10.1097/MOT.0000000000000864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Clearfield E, Miller V, Nadglowski J, Barradas K, Al Naber J, Sanyal AJ, Neuschwander-Tetri BA, Messner DA; coreNASH Panel. coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatol Commun 2021;5:774-85. [PMID: 34027268 DOI: 10.1002/hep4.1678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
131 Aghaulor B, VanWagner LB. Cardiac and Pulmonary Vascular Risk Stratification in Liver Transplantation. Clin Liver Dis 2021;25:157-77. [PMID: 33978576 DOI: 10.1016/j.cld.2020.08.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
132 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
133 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
134 Charatcharoenwitthaya P, Liangpunsakul S, Piratvisuth T. Alcohol-Associated Liver Disease: East Versus West. Clin Liver Dis (Hoboken) 2020;16:231-5. [PMID: 33489093 DOI: 10.1002/cld.920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Caputo F, Testino G. Orthotopic liver transplantation for patients with end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis. Minerva Surg 2021;76:444-9. [PMID: 33433074 DOI: 10.23736/S2724-5691.20.08685-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Decharatanachart P, Chaiteerakij R, Tiyarattanachai T, Treeprasertsuk S. Application of artificial intelligence in chronic liver diseases: a systematic review and meta-analysis. BMC Gastroenterol 2021;21:10. [PMID: 33407169 DOI: 10.1186/s12876-020-01585-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
137 Spiritos Z, Abdelmalek MF. Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:13. [PMID: 33409407 DOI: 10.21037/tgh.2020.02.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
138 Wu Y, Fang F, Wang Z, Wen P, Fan J. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation. Eur J Clin Pharmacol 2021;77:859-67. [PMID: 33386894 DOI: 10.1007/s00228-020-03058-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Billeter AT, Müller PC, Albrecht T, Roessler S, Löffler M, Lemekhova A, Mehrabi A, Müller-Stich BP, Hoffmann K. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis. J Gastrointest Surg 2021;25:1193-202. [PMID: 32378092 DOI: 10.1007/s11605-020-04628-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
140 Serfert Y, Wedemeyer H. Hepatitis C – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. Springer Reference Pflege – Therapie – Gesundheit 2021. [DOI: 10.1007/978-3-662-62426-5_70] [Reference Citation Analysis]
141 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 11.5] [Reference Citation Analysis]
142 Manka PP, Kaya E, Canbay A, Syn WK. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3676-88. [PMID: 34410573 DOI: 10.1007/s10620-021-07206-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Alshuwaykh O, Kwong A, Goel A, Cheung A, Dhanasekaran R, Ahmed A, Daugherty T, Dronamraju D, Kumari R, Kim WR, Nguyen MH, Esquivel CO, Concepcion W, Melcher M, Bonham A, Pham T, Gallo A, Kwo PY. Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. Hepatol Commun 2021;5:516-25. [PMID: 33681683 DOI: 10.1002/hep4.1644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
144 Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:592373. [PMID: 33424768 DOI: 10.3389/fendo.2020.592373] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
145 Wang L, Zhi Y, Ye Y, Zhang M, Ma X, Tie H, Ma X, Zheng N, Xia W, Song Y. Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation. Biomed Res Int 2020;2020:8829346. [PMID: 33415161 DOI: 10.1155/2020/8829346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Wei D, Wu S, Liu J, Zhang X, Guan X, Gao L, Xu Z. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro. Can J Physiol Pharmacol 2021;99:775-85. [PMID: 33290156 DOI: 10.1139/cjpp-2020-0259] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
147 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Tonon M, Piano S. Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. Clin Mol Hepatol 2021;27:94-6. [PMID: 33317236 DOI: 10.3350/cmh.2020.0305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Huanan C, Sangsang L, Amoah AN, Yacong B, Xuejiao C, Zhan S, Guodong W, Jian H, Songhe S, Quanjun L. Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. BMJ Open 2020;10:e039804. [PMID: 33247011 DOI: 10.1136/bmjopen-2020-039804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
150 Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
151 Tao L, Yi Y, Chen Y, Zhang H, Orning P, Lien E, Jie J, Zhang W, Xu Q, Li Y, Ding Z, Wu C, Ding Q, Wang J, Zhang J, Weng D. RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages. Cell Death Differ 2021;28:1418-33. [PMID: 33208891 DOI: 10.1038/s41418-020-00668-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
152 Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct 2020;6:e605. [PMID: 33134485 DOI: 10.1097/TXD.0000000000001060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
153 Agbim U, Satapathy SK. PRO: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes. Clin Liver Dis (Hoboken) 2020;16:127-31. [PMID: 33163162 DOI: 10.1002/cld.932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
154 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 302] [Cited by in F6Publishing: 317] [Article Influence: 100.7] [Reference Citation Analysis]
155 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology 2020;72:1605-16. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 222] [Cited by in F6Publishing: 196] [Article Influence: 74.0] [Reference Citation Analysis]
156 Hyun J, Jung Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8138. [PMID: 33143364 DOI: 10.3390/ijms21218138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
157 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. J Med Ultrasonics 2020;47:511-20. [DOI: 10.1007/s10396-020-01058-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
158 Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020;104:104-12. [PMID: 31283688 DOI: 10.1097/TP.0000000000002816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
159 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
160 Said A, Weiss M, Varhelyi A, Farago R, Ballweg C, Rice J, Agarwal P, Fernandez L, Foley D. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Transpl Infect Dis.  2020: e13466. [PMID: 32931616 DOI: 10.1111/tid.13466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
161 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020; 10(9): 256-266 [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
162 Wang S, Toy M, Hang Pham TT, So S. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS One 2020;15:e0239393. [PMID: 32946502 DOI: 10.1371/journal.pone.0239393] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
163 Price J, Escheik C, Weinstein A, Winter P, Gerber L, Younossi Z. Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. J Clin Hypertens (Greenwich) 2020;22:1915-23. [PMID: 32941676 DOI: 10.1111/jch.13938] [Reference Citation Analysis]
164 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
165 Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020;73:540-8. [PMID: 32243960 DOI: 10.1016/j.jhep.2020.03.031] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 19.0] [Reference Citation Analysis]
166 Mikolasevic I, Lukic A, Juric T, Klapan M, Madzar P, Krolo N, Kolovrat D, Jurica I, Kedmenec I, Kihas D, Ilovaca D, Erstic I, Haralovic V, Cavlina D, Dejhalla E, Erdeljac D, Vukalovic B, Skenderevic N, Milic S. Non-alcoholic fatty liver disease and transient elastography. Exploration of Medicine 2020;1:205-17. [DOI: 10.37349/emed.2020.00014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Wang CQ, Buggs J, Rogers E, Boyd A, Kumar A, Kemmer N. Hepatitis C and Racial Disparity in Liver Transplant Waitlist Additions : Separate Not Equal. Am Surg 2020;86:985-90. [PMID: 32816524 DOI: 10.1177/0003134820942178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Aslam S, Buggs J, Melo S, Ermekbaeva A, Rogers E, Shaw R, Kumar A, Kemmer N. The Association Between Alcoholic Liver Disease and Alcohol Tax. The American Surgeon 2021;87:92-6. [DOI: 10.1177/0003134820945223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, Macías-Kauffer L, González-González I, Hernández-Pando R, Gómez-Pérez F, Campos-Pérez F, Aguilar-Salinas C, Larrieta-Carrasco E, Villarreal-Molina T, Wang Z, Lusis AJ, Hazen SL, Huertas-Vazquez A, Canizales-Quinteros S. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab 2021;47:101183. [PMID: 32791310 DOI: 10.1016/j.diabet.2020.07.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
170 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
171 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020; 26(28): 4018-4035 [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
172 Marín-zuluaga JI, Vergara-cadavid J, Cajiao-castro L, Arroyave-zuluaga D, Castro-sánchez S, Ceballos-ramírez L, Muñoz-maya O, Díaz-ramírez GS. Caracterización, manejo y pronóstico de una cohorte de pacientes cirróticos con carcinoma hepatocelular. Hospital Pablo Tobón Uribe 2012-2018. Hepatología 2020. [DOI: 10.52784/27112330.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, Zhang Q, Du Z, Gai Z, Wu J, Li Y. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2020;2020:4020249. [PMID: 32733940 DOI: 10.1155/2020/4020249] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 9.7] [Reference Citation Analysis]
174 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 24.3] [Reference Citation Analysis]
175 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
176 Povero D, Yamashita H, Ren W, Subramanian MG, Myers RP, Eguchi A, Simonetto DA, Goodman ZD, Harrison SA, Sanyal AJ, Bosch J, Feldstein AE. Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. Hepatol Commun 2020;4:1263-78. [PMID: 32923831 DOI: 10.1002/hep4.1556] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
177 Mohagheghi S, Khajehahmadi Z, Nikeghbalian S, Alavian SM, Doosti-Irani A, Khodadadi I, Karimi J, Sharafi H, Tavilani H. Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. Eur J Gastroenterol Hepatol 2020;32:844-50. [PMID: 31688307 DOI: 10.1097/MEG.0000000000001590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
178 Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020;21:372-84. [PMID: 32369237 DOI: 10.1111/1751-2980.12871] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
179 Vusirikala A, Thomas T, Bhala N, Tahrani AA, Thomas GN, Nirantharakumar K. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord 2020;20:96. [PMID: 32605642 DOI: 10.1186/s12902-020-00582-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
180 Chen J, Deng X, Liu Y, Tan Q, Huang G, Che Q, Guo J, Su Z. Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe? Int J Biol Sci 2020;16:2367-78. [PMID: 32760204 DOI: 10.7150/ijbs.47143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
181 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
182 Pandit H, Li Y, Zheng Q, Guo W, Yu Y, Li S, Martin RCG. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget 2020;11:2047-60. [PMID: 32547703 DOI: 10.18632/oncotarget.27454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
183 Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S, Loomba R. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;51:1305-20. [PMID: 32383295 DOI: 10.1111/apt.15738] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
184 Wang Y, Wong GL, He FP, Sun J, Chan AW, Yang J, Shu SS, Liang X, Tse YK, Fan XT, Hou J, Chan HL, Wong VW. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. Gut 2020;69:1116-26. [PMID: 31563875 DOI: 10.1136/gutjnl-2019-318841] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
185 Fatourou EM, Tsochatzis EA. Management of metabolic syndrome and cardiovascular risk after liver transplantation. Lancet Gastroenterol Hepatol. 2019;4:731-741. [PMID: 31387736 DOI: 10.1016/s2468-1253(19)30181-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
186 Geervliet E, Bansal R. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020;9. [PMID: 32414178 DOI: 10.3390/cells9051212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
187 Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2020;10:699-712. [PMID: 32389640 DOI: 10.1016/j.jcmgh.2020.04.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
188 Danford CJ, Curry MP. Over 2 Decades of Transplanting Hepatitis C Virus-Positive Liver Allografts: Almost Full Circle With Encouraging Early Results. Liver Transpl 2020;26:626-7. [PMID: 32173967 DOI: 10.1002/lt.25754] [Reference Citation Analysis]
189 Zou B, Yeo YH, Jeong D, Park H, Sheen E, Lee DH, Henry L, Garcia G, Ingelsson E, Cheung R, Nguyen MH. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. Dig Dis Sci 2020;65:1520-8. [PMID: 31598919 DOI: 10.1007/s10620-019-05869-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
190 Fowell AJ, Fancey K, Gamble K, Bicknell K, Dowman JK, Howden P, Aspinall RJ. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterol 2021;12:102-7. [PMID: 33613940 DOI: 10.1136/flgastro-2019-101304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
191 M. Loy V, Rzepczynski A, Joyce C, Bello S, Lu A. Disparity in Transplant Referral Patterns for Alcohol-Related Liver Disease Based on Physician-Dependent Variables. Transplantation Proceedings 2020;52:900-4. [DOI: 10.1016/j.transproceed.2020.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
192 Young S, Rivard M, Kimyon R, Sanghvi T. Accuracy of liver ablation zone prediction in a single 2450 MHz 100 Watt generator model microwave ablation system: An in human study. Diagnostic and Interventional Imaging 2020;101:225-33. [DOI: 10.1016/j.diii.2019.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
193 Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open 2020;3:e201997. [PMID: 32239220 DOI: 10.1001/jamanetworkopen.2020.1997] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
194 Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford) 2020;22:521-8. [PMID: 31431413 DOI: 10.1016/j.hpb.2019.07.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
195 Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 2020;21:953-67. [PMID: 32237916 DOI: 10.1080/14656566.2020.1744564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
196 Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:974-83. [PMID: 31357028 DOI: 10.1016/j.cgh.2019.07.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
197 Leone S, Pellicano R, Testino G, Caputo F. Severe acute alcoholic hepatitis and liver transplantation: recent knowledge. Minerva Gastroenterol Dietol 2020;66:87-9. [PMID: 32218428 DOI: 10.23736/S1121-421X.20.02688-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
198 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
199 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
200 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
201 Wu Y, Zheng Q, Zou B, Yeo YH, Li X, Li J, Xie X, Feng Y, Stave CD, Zhu Q, Cheung R, Nguyen MH. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14:259-269. [PMID: 32130675 DOI: 10.1007/s12072-020-10023-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
202 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
203 Bakulin IG, Belousova LN, Nazarenko LI, Sushilova AG. Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice. jour 2020;1:18-25. [DOI: 10.31146/1682-8658-ecg-170-10-18-25] [Reference Citation Analysis]
204 Chandrakumaran A, Siddiqui MS. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. Gastroenterol Clin North Am 2020;49:165-78. [PMID: 32033762 DOI: 10.1016/j.gtc.2019.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, Perola M, Färkkilä M, Jula A. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. Hepatology 2020;71:835-48. [PMID: 31323122 DOI: 10.1002/hep.30864] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 19.7] [Reference Citation Analysis]
206 Shili-Masmoudi S, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9. [PMID: 31749300 DOI: 10.1111/liv.14301] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
207 Bojunga J. Diabetestherapie bei nichtalkoholischer Fettlebererkrankung und Leberzirrhose. Gastroenterologe 2020;15:96-105. [DOI: 10.1007/s11377-020-00417-y] [Reference Citation Analysis]
208 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
209 Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
210 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
211 Aby ES, Lake JR. Basic principles of liver allocation and development over the years. Curr Opin Organ Transplant 2020;25:99-103. [PMID: 32073495 DOI: 10.1097/MOT.0000000000000732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
212 Jha AK, Lata S. Liver transplantation and cardiac illness: Current evidences and future directions. J Hepatobiliary Pancreat Sci 2020;27:225-41. [PMID: 31975575 DOI: 10.1002/jhbp.715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
213 Haugen CE, Holscher CM, Luo X, Bowring MG, Orandi BJ, Thomas AG, Garonzik-Wang J, Massie AB, Philosophe B, McAdams-DeMarco M, Segev DL. Assessment of Trends in Transplantation of Liver Grafts From Older Donors and Outcomes in Recipients of Liver Grafts From Older Donors, 2003-2016. JAMA Surg 2019;154:441-9. [PMID: 30758494 DOI: 10.1001/jamasurg.2018.5568] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
214 Kriss MS, Burton JR, Rosen HR. Biological Principles and Clinical Issues Underlying Liver Transplantation for Viral‐Induced End‐Stage Liver Disease in the Era of Highly Effective Direct‐Acting Antiviral Agents. The Liver 2020. [DOI: 10.1002/9781119436812.ch69] [Reference Citation Analysis]
215 Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. Eur J Intern Med 2020;75:1-9. [PMID: 32051092 DOI: 10.1016/j.ejim.2020.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
216 Goldberg DS, Vianna RM, Martin EF, Martin P, Arosemena Benitez LR, O’brien CB, Bhamidimarri KR. Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff? Transplantation 2020;104:2538-46. [DOI: 10.1097/tp.0000000000003147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
217 Younossi ZM, Tampi RP, Nader F, Younossi IM, Cable R, Srishord M, Racila A. Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. Liver Int 2020;40:308-18. [PMID: 31705834 DOI: 10.1111/liv.14292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Shalimar, Kumar R, Rout G, Kumar R, Yadav R, Das P, Aggarwal S, Gunjan D, Saraya A, Nayak B. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:32-41. [PMID: 32185692 DOI: 10.1007/s12664-019-00991-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
219 Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 2020;72:1-12. [PMID: 32016853 DOI: 10.1007/s43440-019-00020-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
220 Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, Kedia SK, Aithal GP, Bhamidimarri KR, Duseja A, Maiwall R, Maliakkal B, Jalal P, Patel K, Puri P, Ravinuthala R, Wong VW, Abdelmalek MF, Ahmed A, Thuluvath PJ, Singal AK; Global NAFLD Consortium. Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transpl 2020;26:68-79. [PMID: 31665561 DOI: 10.1002/lt.25672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
221 Serfert Y, Wedemeyer H. Hepatitis C – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. Springer Reference Pflege – Therapie – Gesundheit 2020. [DOI: 10.1007/978-3-662-55793-8_70-1] [Reference Citation Analysis]
222 Singal AK, Satapathy SK, Reau N, Wong R, Kuo YF. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis 2020;52:98-101. [PMID: 31582326 DOI: 10.1016/j.dld.2019.08.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
223 Rodrigues PM, Lapitz A, Simão AL, Perugorria MJ, Arrese M, Castro RE, Banales JM. Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. NAFLD and NASH 2020. [DOI: 10.1007/978-3-030-37173-9_9] [Reference Citation Analysis]
224 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020;71:306-33. [PMID: 31314133 DOI: 10.1002/hep.30866] [Cited by in Crossref: 262] [Cited by in F6Publishing: 209] [Article Influence: 87.3] [Reference Citation Analysis]
225 Young K, Liu B, Bhuket T, Wong RJ. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals. J Clin Exp Hepatol 2020;10:581-9. [PMID: 33311895 DOI: 10.1016/j.jceh.2020.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
226 Vandromme M, Jun T, Perumalswami P, Dudley JT, Branch A, Li L. Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes. Pac Symp Biocomput 2020;25:91-102. [PMID: 31797589] [Reference Citation Analysis]
227 Alsahhar JS, Elwir S. Epidemiology and Natural History of Chronic Liver Disease. The Critically Ill Cirrhotic Patient 2020. [DOI: 10.1007/978-3-030-24490-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Shirazi F, Wang J, Wong RJ. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. J Clin Exp Hepatol 2020;10:30-6. [PMID: 32025164 DOI: 10.1016/j.jceh.2019.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
229 Valenti L, Pelusi S. The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Logge WB, Morley KC, Haber PS. GABA(B) Receptors and Alcohol Use Disorders: Clinical Studies. Curr Top Behav Neurosci 2022;52:195-212. [PMID: 33580440 DOI: 10.1007/7854_2020_182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
231 Wang Y, Wen H, Fu J, Cai L, Li PL, Zhao CL, Dong ZF, Ma JP, Wang X, Tian H, Zhang Y, Liu Y, Cai J, She ZG, Huang Z, Li W, Li H. Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. Hepatology 2020;71:93-111. [PMID: 31222801 DOI: 10.1002/hep.30822] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
232 de Ledinghen V. Fibrosis Assessment in Patients with NAFLD. Liver Elastography 2020. [DOI: 10.1007/978-3-030-40542-7_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Testino G, Vignoli T, Patussi V, Scafato E, Caputo F; SIA board (Appendix A) and the external expert supervisors (Appendix B). Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020;52:21-32. [PMID: 31757596 DOI: 10.1016/j.dld.2019.09.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
234 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
235 De Chiara F, Ureta Checcllo C, Ramón Azcón J. High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths. Nutrients 2019;11:E2985. [PMID: 31817648 DOI: 10.3390/nu11122985] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
236 Nangia G, Borges K, Reddy KR. Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019;26:1362-71. [PMID: 31111619 DOI: 10.1111/jvh.13130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
237 Godfrey EL, Malik TH, Lai JC, Mindikoglu AL, Galván NTN, Cotton RT, O'Mahony CA, Goss JA, Rana A. The decreasing predictive power of MELD in an era of changing etiology of liver disease. Am J Transplant 2019;19:3299-307. [PMID: 31394020 DOI: 10.1111/ajt.15559] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
238 Samji NS, Verma R, Keri KC, Singal AK, Ahmed A, Rinella M, Bernstein D, Abdelmalek MF, Satapathy SK. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci 2019;64:3413-30. [PMID: 31312990 DOI: 10.1007/s10620-019-05716-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
239 Mazur RD, Goldberg DS. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers. Liver Transpl 2019;25:1800-10. [PMID: 31539195 DOI: 10.1002/lt.25644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
240 Skladaný Ĺ, Mesárošová Z, Bachová B, Stančík M, Dedinská I. Alcohol-Related Liver Disease as a New Risk Factor for Post-transplant Diabetes After Liver Transplantation. Transplantation Proceedings 2019;51:3369-74. [DOI: 10.1016/j.transproceed.2019.07.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
241 Hosseini V, Maroufi NF, Saghati S, Asadi N, Darabi M, Ahmad SNS, Hosseinkhani H, Rahbarghazi R. Current progress in hepatic tissue regeneration by tissue engineering. J Transl Med 2019;17:383. [PMID: 31752920 DOI: 10.1186/s12967-019-02137-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
242 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Nonalcoholic Fatty Liver Disease - An Update 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
243 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
244 Olave MC, Gurung A, Mistry PK, Kakar S, Yeh M, Xu M, Wu TT, Torbenson M, Jain D. Etiology of cirrhosis in the young. Hum Pathol 2020;96:96-103. [PMID: 31698008 DOI: 10.1016/j.humpath.2019.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
245 Young S, Sanghvi T, Rubin N, Hall D, Roller L, Charaf Y, Golzarian J. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis. Cardiovasc Intervent Radiol 2020;43:65-75. [PMID: 31686136 DOI: 10.1007/s00270-019-02363-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Borro P, Testino G, Pellicano R, Caputo F. Early detection of hepatocellular carcinoma in alcoholic liver disease. Panminerva Med 2021;63:551-2. [PMID: 31670497 DOI: 10.23736/S0031-0808.19.03763-7] [Reference Citation Analysis]
247 Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res 2019;49:1256-62. [PMID: 31495973 DOI: 10.1111/hepr.13425] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
248 Svegliati-baroni G, Pierantonelli I, Torquato P, Marinelli R, Ferreri C, Chatgilialoglu C, Bartolini D, Galli F. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radical Biology and Medicine 2019;144:293-309. [DOI: 10.1016/j.freeradbiomed.2019.05.029] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 20.0] [Reference Citation Analysis]
249 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
250 Zou ZY, Shen B, Fan JG. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1764-72. [PMID: 30918952 DOI: 10.1093/ibd/izz043] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
251 Mccarron S, Bathon B, Abbey D, Conlon DM, Rader D, Olthoff K, Shaked A, Raabe T. NASH patient liver derived organoids exhibit patient specific NASH phenotypes and drug responses.. [DOI: 10.1101/791467] [Reference Citation Analysis]
252 Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig 2019;39:631-41. [PMID: 30993553 DOI: 10.1007/s40261-019-00785-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
253 Bojunga J, Meyer G, Mondorf A. Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen. Info Diabetol 2019;13:30-40. [DOI: 10.1007/s15034-019-1527-1] [Reference Citation Analysis]
254 Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int 2019;39:1661-71. [PMID: 31081997 DOI: 10.1111/liv.14135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
255 Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30. [PMID: 31278377 DOI: 10.1038/s41575-019-0169-z] [Cited by in Crossref: 120] [Cited by in F6Publishing: 117] [Article Influence: 30.0] [Reference Citation Analysis]
256 Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2019;17:2093-2100.e3. [PMID: 30639779 DOI: 10.1016/j.cgh.2019.01.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
257 Adejumo AC, Kim D, Iqbal U, Yoo ER, Boursiquot BC, Cholankeril G, Wong RJ, Kwo PY, Ahmed A. Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. J Palliat Med 2020;23:97-106. [PMID: 31397615 DOI: 10.1089/jpm.2019.0100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
258 Serin A, Sahin T, Arikan BT, Emek E, Bozkurt B, Tokat Y. A Changing Etiologic Scenario in Liver Transplantation: A Single-Center Cohort Study From Turkey. Transplant Proc 2019;51:2416-9. [PMID: 31402253 DOI: 10.1016/j.transproceed.2019.01.190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
259 Ukpong T, Mantry P. PRO: Patients With Decompensated Cirrhosis Listed for Liver Transplantation Should Be Treated Pretransplant. Clin Liver Dis (Hoboken) 2019;14:16-9. [PMID: 31391931 DOI: 10.1002/cld.808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Durand F, Pavesi M, Cheung R. Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand? J Hepatol 2019;71:240-2. [PMID: 31229271 DOI: 10.1016/j.jhep.2019.05.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
261 Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol 2019;71:313-22. [PMID: 31071367 DOI: 10.1016/j.jhep.2019.04.011] [Cited by in Crossref: 141] [Cited by in F6Publishing: 138] [Article Influence: 35.3] [Reference Citation Analysis]
262 Wong RJ, Tran T, Kaufman H, Niles J, Gish R. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. PLoS One 2019;14:e0220612. [PMID: 31369606 DOI: 10.1371/journal.pone.0220612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
263 Parikh ND, Marrero WJ, Wang J, Steuer J, Tapper EB, Konerman M, Singal AG, Hutton DW, Byon E, Lavieri MS. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology 2019;70:487-95. [PMID: 28833326 DOI: 10.1002/hep.29473] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
264 Likhitsup A, Hassan A, Mellinger J, Askari F, Winder GS, Saeed N, Sonnenday CJ, Sharma P, Fontana RJ. Impact of a Prohibitive Versus Restrictive Tobacco Policy on Liver Transplant Candidate Outcomes. Liver Transpl 2019;25:1165-76. [PMID: 31116906 DOI: 10.1002/lt.25497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
265 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
266 Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900487. [PMID: 31322321 DOI: 10.1002/mnfr.201900487] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
267 Da BL, Surana P, Schueler SA, Jalaly NY, Kamal N, Taneja S, Vittal A, Gilman CL, Heller T, Koh C. Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease. Hepatol Commun 2019;3:1271-80. [PMID: 31497747 DOI: 10.1002/hep4.1394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
268 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
269 Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
270 Patel SS, Lin FP, Rodriguez VA, Bhati C, John BV, Pence T, Siddiqui MB, Sima AP, Abbate A, Reichman T, Siddiqui MS. The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver Int 2019;39:1363-71. [PMID: 30848862 DOI: 10.1111/liv.14092] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
271 Yao Y, Miao X, Zhu D, Li D, Zhang Y, Song C, Liu K. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Endocrine 2019;65:227-37. [PMID: 31243652 DOI: 10.1007/s12020-019-01982-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
272 Orman ES, Roberts A, Ghabril M, Nephew L, Desai AP, Patidar K, Chalasani N. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. JAMA Netw Open 2019;2:e196412. [PMID: 31251379 DOI: 10.1001/jamanetworkopen.2019.6412] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
273 Saviano A, Baumert TF. Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease. Hepatobiliary Surg Nutr 2019;8:307-10. [PMID: 31245422 DOI: 10.21037/hbsn.2019.01.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
274 Hirode G, Vittinghoff E, Wong RJ. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-57. [PMID: 30863953 DOI: 10.1007/s10620-019-05576-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
275 Mahmud N, Halpern S, Farrell R, Ventura K, Thomasson A, Lewis H, Olthoff KM, Levine MH, Nazarian S, Khungar V. An Advanced Practice Practitioner-Based Program to Reduce 30- and 90-Day Readmissions After Liver Transplantation. Liver Transpl 2019;25:901-10. [PMID: 30947393 DOI: 10.1002/lt.25466] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
276 Shingina A, DeWitt PE, Dodge JL, Biggins SW, Gralla J, Sprague D, Bambha K. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC. Transplantation. 2019;103:140-148. [PMID: 30451739 DOI: 10.1097/tp.0000000000002497] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
277 Narayanan P, Mara K, Izzy M, Dierkhising R, Heimbach J, Allen AM, Watt KD. Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation. Transplantation. 2019;103:e14-e21. [PMID: 29994981 DOI: 10.1097/tp.0000000000002317] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
278 Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103:22-27. [PMID: 30335697 DOI: 10.1097/tp.0000000000002484] [Cited by in Crossref: 196] [Cited by in F6Publishing: 205] [Article Influence: 49.0] [Reference Citation Analysis]
279 Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018;23:169-174. [PMID: 29356708 DOI: 10.1097/mot.0000000000000502] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
280 Kieckhaefer JE, Maina F, Wells RG, Wangensteen KJ. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. Semin Liver Dis 2019;39:261-74. [PMID: 30912094 DOI: 10.1055/s-0039-1678725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
281 Axley P, Ahmed Z, Arora S, Haas A, Kuo YF, Kamath PS, Singal AK. NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. Liver Transpl 2019;25:695-705. [PMID: 30861321 DOI: 10.1002/lt.25443] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
282 Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther 2019;17:311-25. [PMID: 30856022 DOI: 10.1080/14787210.2019.1588112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
283 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
284 Shen NT, Londono C, Gold S, Wu A, Mages KC, Brown RSJ. Systematic review with meta-analysis on transplantation for alcohol-related liver disease: Very low evidence of improved outcomes. World J Gastroenterol 2019; 25(13): 1628-1639 [PMID: 30983822 DOI: 10.3748/wjg.v25.i13.1628] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
285 Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol 2019;70:745-58. [PMID: 30576701 DOI: 10.1016/j.jhep.2018.12.009] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 26.3] [Reference Citation Analysis]
286 Suppli MP, Rigbolt KTG, Veidal SS, Heebøll S, Eriksen PL, Demant M, Bagger JI, Nielsen JC, Oró D, Thrane SW, Lund A, Strandberg C, Kønig MJ, Vilsbøll T, Vrang N, Thomsen KL, Grønbæk H, Jelsing J, Hansen HH, Knop FK. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol 2019;316:G462-72. [PMID: 30653341 DOI: 10.1152/ajpgi.00358.2018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 25.5] [Reference Citation Analysis]
287 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 574] [Cited by in F6Publishing: 585] [Article Influence: 143.5] [Reference Citation Analysis]
288 Arora SS, Axley P, Ahmed Z, Satapathy SK, Wong R, Kuo YF, Singal AK. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int. 2019;32:854-864. [PMID: 30866110 DOI: 10.1111/tri.13424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
289 Piano S, Tonon M, Angeli P. Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. Liver Transpl 2019;25:362-4. [PMID: 30657244 DOI: 10.1002/lt.25413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019;17:748-755.e3. [PMID: 29908364 DOI: 10.1016/j.cgh.2018.05.057] [Cited by in Crossref: 384] [Cited by in F6Publishing: 389] [Article Influence: 96.0] [Reference Citation Analysis]
291 Su F, Ioannou GN. Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy. Clin Liver Dis (Hoboken) 2019;13:6-12. [PMID: 31168359 DOI: 10.1002/cld.781] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
292 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh) 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 60] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
293 Parrish NF, Feurer ID, Matsuoka LK, Rega SA, Perri R, Alexopoulos SP. The Changing Face of Liver Transplantation in the United States: The Effect of HCV Antiviral Eras on Transplantation Trends and Outcomes. Transplant Direct 2019;5:e427. [PMID: 30882032 DOI: 10.1097/TXD.0000000000000866] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
294 Kern B, Feurstein B, Fritz J, Fabritius C, Sucher R, Graziadei I, Bale R, Tilg H, Zoller H, Newsome P, Eschertzhuber S, Margreiter R, Öfner D, Schneeberger S. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol 2019;31:205-10. [PMID: 30320609 DOI: 10.1097/MEG.0000000000001270] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
295 Thanapirom K, Tsochatzis EA. Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments. Hepatobiliary Surg Nutr 2019;8:77-9. [PMID: 30881974 DOI: 10.21037/hbsn.2018.11.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
296 Godfrey EL, Stribling R, Rana A. Liver Transplantation for Alcoholic Liver Disease: An Update. Clin Liver Dis 2019;23:127-39. [PMID: 30454827 DOI: 10.1016/j.cld.2018.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
297 Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, McPherson S, Mutimer D, Gelson W. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral Hepat 2019;26:231-5. [PMID: 30339294 DOI: 10.1111/jvh.13022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
298 Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. Hepatology 2019;69:564-72. [PMID: 30180285 DOI: 10.1002/hep.30254] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 22.8] [Reference Citation Analysis]
299 Mellinger JL, Fernandez A, Shedden K, Winder GS, Fontana RJ, Volk ML, Blow FC, Lok ASF. Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. Alcohol Clin Exp Res 2019;43:334-41. [PMID: 30667521 DOI: 10.1111/acer.13944] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
300 Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughan G, Crawford M, Angus P, Jones R, Gane E, Munn S, Macdonald G, Fawcett J, Wigg A, Chen J, Fink M, Adams LA. Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. Liver Transpl 2019;25:25-34. [PMID: 30609187 DOI: 10.1002/lt.25361] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
301 Miyake T, Hiasa Y. Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. The Evolving Landscape of Liver Cirrhosis Management 2019. [DOI: 10.1007/978-981-13-7979-6_1] [Reference Citation Analysis]
302 Ata N, Ayloo S, Tsung A, Molinari M. Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States. HPB (Oxford) 2019;21:67-76. [PMID: 30691592 DOI: 10.1016/j.hpb.2018.06.1797] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
303 Carrion AF, Martin P. When to Refer for Liver Transplantation. Am J Gastroenterol 2019;114:7-10. [PMID: 30171217 DOI: 10.1038/s41395-018-0242-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
304 Asrani SK, Hall L, Hagan M, Sharma S, Yeramaneni S, Trotter J, Talwalkar J, Kanwal F. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol 2019;114:98-106. [PMID: 30333543 DOI: 10.1038/s41395-018-0365-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
305 Nash R, Golden E, Dew MA, Dimartini AF. Mental Health in Chronic and End-Stage Liver Disease. Psychosocial Care of End-Stage Organ Disease and Transplant Patients 2019. [DOI: 10.1007/978-3-319-94914-7_12] [Reference Citation Analysis]
306 Goel A, Siddique O, Ahmed A. End-Stage Liver Disease and Indications for Liver Transplantation. Psychosocial Care of End-Stage Organ Disease and Transplant Patients 2019. [DOI: 10.1007/978-3-319-94914-7_11] [Reference Citation Analysis]
307 Korobka VL, Pak ES, Pasechnikov VD, Kostrykin MY. Compensation of HCV-associated decompensated cirrhosis treated with modern direct-acting antiviral agents. Dok gastroenterol 2019;8:11. [DOI: 10.17116/dokgastro2019804-05111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
308 Bodek D, Patel P, Ahlawat S, Orosz E, Nasereddin T, Pyrsopoulos N. Superior Performance of Teaching and Transplant Hospitals in the Management of Hepatic Encephalopathy from 2007 to 2014. J Clin Transl Hepatol 2018;6:362-71. [PMID: 30637212 DOI: 10.14218/JCTH.2017.00078] [Reference Citation Analysis]
309 Ezaz G, Tapper EB. Driving in the dark: cirrhosis in young adults. Lancet Gastroenterol Hepatol 2019;4:189-90. [PMID: 30573391 DOI: 10.1016/S2468-1253(18)30419-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
310 Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2019;4:217-26. [PMID: 30573390 DOI: 10.1016/S2468-1253(18)30339-X] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
311 Younossi ZM. Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. Hepatology 2018;68:2405-12. [PMID: 30070714 DOI: 10.1002/hep.30125] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
312 Roccaro GA, Mitrani R, Hwang WT, Forde KA, Reddy KR. Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease. Liver Transpl 2018;24:1665-72. [PMID: 30291672 DOI: 10.1002/lt.25351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
313 Paul S, Charlton M. Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation. Curr Hepatology Rep 2018;17:367-376. [DOI: 10.1007/s11901-018-0429-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
314 Gitto S, Marra F, De Maria N, Bihl F, Villa E, Andreone P, Burra P. Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Expert Review of Gastroenterology & Hepatology 2018;13:173-8. [DOI: 10.1080/17474124.2019.1551132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
315 Zhang Z, Xie G, Liang L, Liu H, Pan J, Cheng H, Wang H, Qu A, Wang Y. RIPK3-Mediated Necroptosis and Neutrophil Infiltration Are Associated with Poor Prognosis in Patients with Alcoholic Cirrhosis. J Immunol Res 2018;2018:1509851. [PMID: 30596105 DOI: 10.1155/2018/1509851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
316 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol 2018;113:1649-59. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 271] [Cited by in F6Publishing: 265] [Article Influence: 54.2] [Reference Citation Analysis]
317 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis 2018;22:703-22. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
318 Wieland A, Kohli R. Non-Alcoholic Steatohepatitis as a Growing Indication for Liver Transplantation: The Evolving Gender and Ethnic Trends. Am J Gastroenterol 2018;113:1588-9. [PMID: 30353054 DOI: 10.1038/s41395-018-0373-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
319 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
320 Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, Zanetto A, Shalaby S, Cillo U, Zanus G, Angeli P, Burra P. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World J Gastroenterol 2018; 24(38): 4403-4411 [PMID: 30344424 DOI: 10.3748/wjg.v24.i38.4403] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
321 Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, Charco R, Zieniewicz K, De Carlis L, Duvoux C; all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol 2018;69:810-7. [PMID: 29940268 DOI: 10.1016/j.jhep.2018.06.010] [Cited by in Crossref: 159] [Cited by in F6Publishing: 160] [Article Influence: 31.8] [Reference Citation Analysis]
322 Law JL, Logan M, Landi A, Tyrrell DL, Houghton M. Progress toward approval of an HCV vaccine. CanLivJ 2018;1:130-138. [DOI: 10.3138/canlivj.2018.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
323 Kwong AJ, Kim WR, Flemming JA. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. Hepatology 2018;68:1288-97. [PMID: 29672886 DOI: 10.1002/hep.30045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
324 de Franchis R, Krag A. Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy? J Hepatol 2018;69:769-71. [PMID: 30227915 DOI: 10.1016/j.jhep.2018.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
325 Terrault NA, Pageaux GP. A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! J Hepatol 2018;69:767-8. [PMID: 30104027 DOI: 10.1016/j.jhep.2018.07.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
326 Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. J Hepatol 2018;69:982-4. [PMID: 30089577 DOI: 10.1016/j.jhep.2018.07.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
327 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, McCormack L, Gadano A, Boin ISFF, García P, Silva M; Latin American Liver Research, Education, Awareness Network (LALREAN). A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol 2018;42:443-52. [PMID: 29773419 DOI: 10.1016/j.clinre.2018.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
328 Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology 2018;155:1154-1163.e3. [PMID: 30009816 DOI: 10.1053/j.gastro.2018.07.008] [Cited by in Crossref: 127] [Cited by in F6Publishing: 132] [Article Influence: 25.4] [Reference Citation Analysis]
329 Saab S, Challita Y, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo FA, El-Kabany MM, Han SB, Grotts J, Agopian VG, Busuttil RW. Elimination of Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol 2018;6:247-50. [PMID: 30271735 DOI: 10.14218/JCTH.2017.00079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
330 Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
331 Adejumo AC, Adegbala OM, Adejumo KL, Bukong TN. Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis. Can J Gastroenterol Hepatol 2018;2018:9430953. [PMID: 30345261 DOI: 10.1155/2018/9430953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
332 Lam B, Kurzke K, Younossi Z. The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Curr Hepatology Rep 2018;17:345-9. [DOI: 10.1007/s11901-018-0423-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
333 Testino G, Leone S, Fagoonee S, Pellicano R. Alcoholic liver fibrosis: detection and treatment. Minerva Med 2018;109:457-71. [PMID: 30221911 DOI: 10.23736/S0026-4806.18.05844-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
334 Zheng Y, Wang M, Zheng P, Tang X, Ji G. Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease. Sci Rep 2018;8:13681. [PMID: 30209324 DOI: 10.1038/s41598-018-31708-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
335 Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, Blow FC, Lok ASF. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 2018;68:872-82. [PMID: 29579356 DOI: 10.1002/hep.29887] [Cited by in Crossref: 116] [Cited by in F6Publishing: 96] [Article Influence: 23.2] [Reference Citation Analysis]
336 Patel YA, Gifford EJ, Glass LM, Turner MJ, Han B, Moylan CA, Choi S, Suzuki A, Provenzale D, Hunt CM. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Dig Dis Sci 2018;63:2259-66. [PMID: 29779083 DOI: 10.1007/s10620-018-5123-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
337 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 348] [Cited by in F6Publishing: 382] [Article Influence: 69.6] [Reference Citation Analysis]
338 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
339 Musso G, Cassader M, Paschetta E, Gambino R. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology 2018;155:282-302.e8. [PMID: 29906416 DOI: 10.1053/j.gastro.2018.06.031] [Cited by in Crossref: 148] [Cited by in F6Publishing: 149] [Article Influence: 29.6] [Reference Citation Analysis]
340 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [PMID: 29844588 DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 277] [Cited by in F6Publishing: 258] [Article Influence: 55.4] [Reference Citation Analysis]
341 Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2018;16:1356-8. [PMID: 29199144 DOI: 10.1016/j.cgh.2017.11.045] [Cited by in Crossref: 143] [Cited by in F6Publishing: 149] [Article Influence: 28.6] [Reference Citation Analysis]
342 Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G, Kim D, Ahmed A. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. J Clin Transl Hepatol. 2018;6:420-424. [PMID: 30637220 DOI: 10.14218/jcth.2018.00010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
343 VanWagner LB. A simple clinical calculator for assessing cardiac event risk in liver transplant candidates: The cardiovascular risk in orthotopic liver transplantation score. Clin Liver Dis (Hoboken) 2018;11:145-8. [PMID: 30319773 DOI: 10.1002/cld.718] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
344 Marroni CA, Fleck Jr AM, Fernandes SA, Galant LH, Mucenic M, de Mattos Meine MH, Mariante-Neto G, Brandão ABM. Liver transplantation and alcoholic liver disease: History, controversies, and considerations. World J Gastroenterol 2018; 24(26): 2785-2805 [PMID: 30018475 DOI: 10.3748/wjg.v24.i26.2785] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 69] [Article Influence: 13.6] [Reference Citation Analysis]
345 López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza Á, Perez-Rojas J, Salcedo M, Benlloch S, Castell JV, Jover R. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep 2018;8:10606. [PMID: 30006517 DOI: 10.1038/s41598-018-28854-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
346 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 1376] [Cited by in F6Publishing: 1444] [Article Influence: 275.2] [Reference Citation Analysis]
347 Crespo G, Trota N, Londoño MC, Mauro E, Baliellas C, Castells L, Castellote J, Tort J, Forns X, Navasa M. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol 2018;69:11-7. [PMID: 29481821 DOI: 10.1016/j.jhep.2018.02.012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 12.4] [Reference Citation Analysis]
348 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 225] [Cited by in F6Publishing: 1] [Article Influence: 45.0] [Reference Citation Analysis]
349 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68:361-71. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 221] [Cited by in F6Publishing: 209] [Article Influence: 44.2] [Reference Citation Analysis]
350 Im GY. Primed for the spotlight: Transplantation for alcohol-associated liver disease. J Hepatol 2018;69:253-4. [PMID: 29627224 DOI: 10.1016/j.jhep.2018.03.014] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
351 Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplantation Reviews 2018;32:142-50. [DOI: 10.1016/j.trre.2018.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
352 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 219] [Cited by in F6Publishing: 210] [Article Influence: 43.8] [Reference Citation Analysis]
353 Cacciola I, Filomia R, Alibrandi A, Franzè MS, Caccamo G, Maimone S, Saitta C, Saffioti F, Squadrito G, Raimondo G. Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. Liver Int 2018;38:1220-9. [PMID: 29194934 DOI: 10.1111/liv.13649] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
354 Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018;6:264-275. [PMID: 30271738 DOI: 10.14218/jcth.2017.00056] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
355 Nazzal M, Lentine KL, Naik AS, Ouseph R, Schnitzler MA, Zhang Z, Randall H, Dharnidharka VR, Segev DL, Kasiske BL, Hess GP, Alhamad T, McAdams-Demarco M, Axelrod DA. Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis. Transplant Direct 2018;4:e364. [PMID: 30046654 DOI: 10.1097/TXD.0000000000000800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
356 Marinho PC, Vieira AB, Pereira PG, Rabelo K, Ciambarella BT, Nascimento ALR, Cortez E, Moura AS, Guimarães FV, Martins MA, Barquero G, Ferreira RN, de Carvalho JJ. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:4956079. [PMID: 29853957 DOI: 10.1155/2018/4956079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
357 Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology 2018;67:2085-95. [PMID: 29222916 DOI: 10.1002/hep.29723] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
358 Berenguer J. Eliminación del virus de la hepatitis C en España: un reto pendiente. Enfermedades Infecciosas y Microbiología Clínica 2018;36:323-4. [DOI: 10.1016/j.eimc.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
359 Tajiri K, Kawai K, Sugiyama T. Reply to "Letter to Editor submitted by Rui Huang et al. entitled potential clinical application of strain elastography in chronic liver diseases". J Gastroenterol 2018;53:797-8. [PMID: 29623438 DOI: 10.1007/s00535-018-1461-3] [Reference Citation Analysis]
360 Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol 2018;113:819-28. [PMID: 29748558 DOI: 10.1038/s41395-018-0049-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
361 Berenguer J. Elimination of hepatitis C virus in Spain: A pending challenge. Enfermedades infecciosas y microbiologia clinica (English ed ) 2018;36:323-324. [DOI: 10.1016/j.eimce.2018.03.006] [Reference Citation Analysis]
362 Huang O, Shah T, Sundarapandiyan D, Akiyama MJ. Orbital Pseudotumor as an Extrahepatic Complication of Chronic HCV Infection. Case Rep Infect Dis 2018;2018:5498953. [PMID: 30002935 DOI: 10.1155/2018/5498953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
363 Takakura K, Oikawa T, Tomita Y, Mizuno Y, Nakano M, Saeki C, Torisu Y, Saruta M. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma. World J Gastroenterol 2018; 24(18): 1989-1994 [PMID: 29760542 DOI: 10.3748/wjg.v24.i18.1989] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
364 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
365 Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken) 2018;11:92-4. [PMID: 30992797 DOI: 10.1002/cld.710] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
366 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol 2018; 24(14): 1491-1506 [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 77] [Article Influence: 14.6] [Reference Citation Analysis]
367 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
368 Viganò L, Lleo A, Aghemo A. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario. Hepatobiliary Surg Nutr 2018;7:130-3. [PMID: 29744343 DOI: 10.21037/hbsn.2018.01.01] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
369 Musso G, Gambino R, Cassader M, Paschetta E, Sircana A. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. Trends in Pharmacological Sciences 2018;39:387-401. [DOI: 10.1016/j.tips.2018.01.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
370 Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24(12): 1353-1360 [PMID: 29599610 DOI: 10.3748/wjg.v24.i12.1353] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
371 Schneekloth TD, Niazi SK, Simonetto DA. Alcoholic hepatitis: appropriate indication for liver transplantation? Curr Opin Organ Transplant 2017;22:578-83. [PMID: 28937405 DOI: 10.1097/MOT.0000000000000468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
372 Charlton M. FGF-19 agonism for NASH: a short study of a long disease. Lancet 2018;391:1124-6. [PMID: 29519501 DOI: 10.1016/S0140-6736(18)30425-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
373 Gawrieh S, Chalasani N. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:189-99. [PMID: 29128056 DOI: 10.1016/j.cld.2017.08.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
374 Younossi ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Liver Transpl 2018;24:166-70. [PMID: 29272073 DOI: 10.1002/lt.25003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
375 Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018; 10(1): 41-50 [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
376 Pogribny IP, Dreval K, Kindrat I, Melnyk S, Jimenez L, de Conti A, Tryndyak V, Pogribna M, Ortega JF, James SJ. Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma. FASEB J. 2018;32:1591-1601. [PMID: 29127188 DOI: 10.1096/fj.201700866r] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
377 Liu H, Wang X, Han R, Zuo K, Yuan X, Li Y, Zhou J, Yan L, Chu Y. Isolation and molecular cloning of hepatocyte growth factor from guinea pig (gHGF), and expression of truncated variant of gHGF with improved anti-fibrotic activity in Escherichia coli. International Journal of Biological Macromolecules 2018;106:908-16. [DOI: 10.1016/j.ijbiomac.2017.08.087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
378 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018;53:362-76. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 366] [Cited by in F6Publishing: 379] [Article Influence: 73.2] [Reference Citation Analysis]
379 Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, Provenzale D, Choi SS, Moylan CA, Hunt CM. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. Aliment Pharmacol Ther 2018;47:268-78. [PMID: 29115682 DOI: 10.1111/apt.14411] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
380 Kling CE, Perkins JD, Carithers RL, Donovan DM, Sibulesky L. Recent trends in liver transplantation for alcoholic liver disease in the United States. World J Hepatol 2017; 9(36): 1315-1321 [PMID: 29359014 DOI: 10.4254/wjh.v9.i36.1315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
381 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Reference Citation Analysis]
382 Shalaby S, Zanetto A, Vitale A, Gambato M, Cillo U, Farinati F, Burra P, Russo FP. Reply. Liver Transpl 2017;23:1630-1. [PMID: 29024423 DOI: 10.1002/lt.24956] [Reference Citation Analysis]
383 Foog DH, Kwok D, Yu BC, Wong VW. Managing HCC in NAFLD. Curr Hepatology Rep 2017;16:374-381. [DOI: 10.1007/s11901-017-0376-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
384 Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. J Hepatol 2017;67:1134-6. [PMID: 28966125 DOI: 10.1016/j.jhep.2017.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
385 Han E, Lee YH. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. Diabetes Metab J 2017;41:430-7. [PMID: 29199410 DOI: 10.4093/dmj.2017.41.6.430] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
386 Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med. 2017;15:200. [PMID: 29121925 DOI: 10.1186/s12916-017-0966-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
387 Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl 2017;23:1415-21. [PMID: 28752920 DOI: 10.1002/lt.24832] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
388 Verna EC. HCV treatment in patients with decompensated liver disease. Clin Liver Dis (Hoboken) 2017;10:83-6. [PMID: 31186892 DOI: 10.1002/cld.663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
389 Klein S, Dufour JF. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol 2017;4:83-98. [PMID: 30191057 DOI: 10.2217/hep-2017-0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
390 Fried MW, Darling JM, Lemon SM. Hepatitis C. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch25] [Reference Citation Analysis]
391 Hagström H. Alcohol, smoking and the liver disease patient. Best Pract Res Clin Gastroenterol 2017;31:537-43. [PMID: 29195673 DOI: 10.1016/j.bpg.2017.09.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
392 Strasser SI. Longterm outcome of the liver graft: A clinician's perspective-recurrent disease, the universal shifting. Liver Transpl 2017;23:S64-9. [PMID: 28779560 DOI: 10.1002/lt.24839] [Reference Citation Analysis]
393 Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017; 23(26): 4669-4674 [PMID: 28765688 DOI: 10.3748/wjg.v23.i26.4669] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
394 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
395 Tsuchiya A, Kojima Y, Ikarashi S, Seino S, Watanabe Y, Kawata Y, Terai S. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflamm Regen. 2017;37:16. [PMID: 29259715 DOI: 10.1186/s41232-017-0045-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 9.8] [Reference Citation Analysis]
396 Lonardo A, Nascimbeni F, Ponz de Leon M. Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? Eur Respir J 2017;49:1700546. [DOI: 10.1183/13993003.00546-2017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
397 Murken DR, Peng AW, Aufhauser DD Jr, Abt PL, Goldberg DS, Levine MH. Same policy, different impact: Center-level effects of share 35 liver allocation. Liver Transpl 2017;23:741-50. [PMID: 28407441 DOI: 10.1002/lt.24769] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
398 Hagström H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Curr Hepatol Rep 2017;16:152-7. [PMID: 28706775 DOI: 10.1007/s11901-017-0343-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
399 van Tilborg M, Maan R, van der Meer AJ, de Knegt RJ. Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Pract Res Clin Gastroenterol 2017;31:219-25. [PMID: 28624110 DOI: 10.1016/j.bpg.2017.04.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
400 [DOI: 10.1101/2020.01.07.895516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]